Groundbreaking scanner seeks to make medical imaging fairer for all

NCT ID NCT04812080

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed pilot study used a new, FDA-cleared total-body PET/CT scanner called EXPLORER to collect imaging data from 20 healthy volunteers who are members of racial or ethnic minority groups. The goal was to gather preliminary information on how the body absorbs a standard imaging tracer, which could help improve future medical scans for diverse populations. Participants also provided blood samples to confirm their ancestry.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help improve medical imaging accuracy for people from diverse racial and ethnic backgrounds.
What could go wrong
This is a very small pilot study with only 20 participants, so results may not apply to everyone. It is designed to gather data, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Aug 2021

Finished

Nov 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Men and women, 18 years of age or older * Member of a Federally recognized racial/ethnic minority population, e.g., African American or Black; Hispanic or Latino; Asian American; Native Hawaiian or Other Pacific Islander; Native American or Alaska Native * Willing and able to fast for at least 6 hours before and for the duration of the scan * Willing to provide urine samples throughout scan visit * Willing to provide blood samples for ancestry analysis * Willing and able to lay motionless in a supine position for up to 60 minutes and for up to 20 minutes at two separate timepoints * Willing and able to give informed consent, personal contact information (phone number, email and postal address), insurance information, and primary care physician contact Exclusion criteria: * No Primary Care Physician * No health insurance * Body weight more than 240 kg (529 pounds) * Any known concomitant acute infection (including upper respiratory infection, genitourinary infections, etc.) * History of metastatic or newly (last 5 years) diagnosed locally invasive cancer * Chemotherapy in the last 5 years * Radiation therapy in the last 3 years * Major surgery within the last 6 months * Pregnancy or breast-feeding * Diabetes * Fasting blood glucose level \> 200 mg/dL before administration of fluorodeoxyglucose (FDG) * Prisoners * Self-reported history of dysphoria or anxiety in closed spaces

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers from racial/ethnic minority populations are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, Davis

    Sacramento, California, 95817, United States